Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis.

BACKGROUND Efforts to mimic euglycemia depend upon targets from epidemiologic studies that rely on episodic measurements reduced to statistical summaries, leaving open the question, "What is normal glycemia?" We postulated that portrayal of euglycemia was possible through application of continuous glucose monitoring (CGM) and a novel analytical tool, the ambulatory glucose profile (AGP). METHODS Individuals with normal glucose tolerance (NGT) and with diabetes used CGM for 30 days. AGP analysis, which graphs CGM data by time without regard to date, was used to characterize glucose exposure, variability, and stability. RESULTS Sixty-two subjects completed the study, employing CGM for 28 +/- 4 days averaging 99 +/- 18 (range, 33-125) readings per day. NGT subjects (n = 32) had a mean CGM of 102 +/- 7 mg/dL, ranging between 94 and 117 mg/dL and averaging 105 +/- 8 mg/dL daytime and 97 +/- 6 mg/dL overnight. Glucose variability, as expressed by the interquartile range, was 21 +/- 4 mg/dL (range, 14-29 mg/dL). Stability in glycemic control (hourly change in the median) for NGT subjects averaged 3 +/- 1 mg/dL/h. Subjects with diabetes (n = 30) were significantly higher on all glycemic characteristics with the exception of the percentage of hypoglycemic (CGM <70 mg/dL) episodes for type 2 diabetes (2.9%), compared to 2.7% for subjects with NGT. CONCLUSIONS CGM technologies enabled collection of verified data under normal living conditions, providing an exceptional vantage point from which to obtain important clinical information. This will facilitate an understanding of the range of euglycemic patterns, provide a sensitive means of detecting impaired glucose tolerance, and help set realistic treatment goals for individuals with diabetes.

[1]  Bruce W Bode,et al.  Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. , 2005, Diabetes care.

[2]  Boris Kovatchev,et al.  Evaluating the clinical accuracy of two continuous glucose sensors using continuous glucose-error grid analysis. , 2005, Diabetes care.

[3]  D Rodbard,et al.  Ambulatory Glucose Profile: Representation of Verified Self-Monitored Blood Glucose Data , 1987, Diabetes Care.

[4]  R. Arky "Doctor, is my sugar normal?". , 2005, The New England journal of medicine.

[5]  Howard Zisser,et al.  Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. , 2006, Diabetes care.

[6]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[7]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[8]  J. Després,et al.  What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. , 2004, Diabetes care.

[9]  C. Saudek,et al.  Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. , 2003, Diabetes.

[10]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[11]  D. Cox,et al.  Evaluating the accuracy of continuous glucose-monitoring sensors: continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. , 2004, Diabetes care.

[12]  A. Novials,et al.  The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. , 2003, Diabetes care.

[13]  T. Kubiak,et al.  Assessment of hypoglycaemia awareness using continuous glucose monitoring , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[14]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[15]  Howard C. Zisser,et al.  Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. , 2007, Diabetes technology & therapeutics.

[16]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[17]  Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. , 2005, The Journal of clinical endocrinology and metabolism.

[18]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[19]  R. Iman,et al.  Rank Transformations as a Bridge between Parametric and Nonparametric Statistics , 1981 .

[20]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[21]  R. Potts,et al.  Physiological differences between interstitial glucose and blood glucose measured in human subjects. , 2003, Diabetes care.

[22]  D. Pereg,et al.  Normal fasting plasma glucose levels and type 2 diabetes in young men. , 2005, The New England journal of medicine.

[23]  R. Walker,et al.  Diagnosing insulin resistance in the general population. , 2001, Diabetes care.

[24]  R. Brazg,et al.  Accuracy of the 5-Day FreeStyle Navigator Continuous Glucose Monitoring System , 2007, Diabetes Care.

[25]  Michael Brownlee,et al.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. , 2006, JAMA.

[26]  I. Deary,et al.  Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[27]  P. Cryer,et al.  Hypoglycemia in diabetes. , 2003, Diabetes care.

[28]  W. Hopfenmüller,et al.  Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes , 2007, Pediatric diabetes.

[29]  D G Altman,et al.  Analysis of serial measurements in medical research. , 1990, BMJ.